These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 32000517)

  • 1. Effect of Uric Acid-Lowering Agents on Cardiovascular Outcome in Patients With Heart Failure: A Systematic Review and Meta-Analysis of Clinical Studies.
    Kanbay M; Afsar B; Siriopol D; Dincer N; Erden N; Yilmaz O; Sag AA; Kuwabara M; Cherney D; Rossignol P; Ortiz A; Covic A
    Angiology; 2020 Apr; 71(4):315-323. PubMed ID: 32000517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allopurinol or oxypurinol in heart failure therapy - a promising new development or end of story?
    Reyes AJ; Leary WP
    Cardiovasc Drugs Ther; 2005 Oct; 19(5):311-3. PubMed ID: 16382292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New Perspectives in Rheumatology: Implications of the Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities Trial and the Associated Food and Drug Administration Public Safety Alert.
    Choi H; Neogi T; Stamp L; Dalbeth N; Terkeltaub R
    Arthritis Rheumatol; 2018 Nov; 70(11):1702-1709. PubMed ID: 29869840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison between febuxostat and allopurinol uric acid-lowering therapy in patients with chronic heart failure and hyperuricemia: a multicenter randomized controlled trial.
    Suzuki S; Yoshihisa A; Yokokawa T; Kobayashi A; Yamaki T; Kunii H; Nakazato K; Tsuda A; Tsuda T; Ishibashi T; Konno I; Yamaguchi O; Machii H; Nozaki N; Niizeki T; Miyamoto T; Takeishi Y;
    J Int Med Res; 2021 Dec; 49(12):3000605211062770. PubMed ID: 34914568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The net clinical benefits of febuxostat versus allopurinol in patients with gout or asymptomatic hyperuricemia - A systematic review and meta-analysis.
    Liu CW; Chang WC; Lee CC; Shau WY; Hsu FS; Wang ML; Chen TC; Lo C; Hwang JJ
    Nutr Metab Cardiovasc Dis; 2019 Oct; 29(10):1011-1022. PubMed ID: 31378626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Uric acid, heart failure survival, and the impact of xanthine oxidase inhibition.
    Harzand A; Tamariz L; Hare JM
    Congest Heart Fail; 2012; 18(3):179-82. PubMed ID: 22587748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in uric acid levels and allopurinol use in chronic heart failure: association with improved survival.
    Gotsman I; Keren A; Lotan C; Zwas DR
    J Card Fail; 2012 Sep; 18(9):694-701. PubMed ID: 22939038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing Cardiovascular Safety of Febuxostat and Allopurinol in the Real World: A Population-Based Cohort Study.
    Su CY; Shen LJ; Hsieh SC; Lin LY; Lin FJ
    Mayo Clin Proc; 2019 Jul; 94(7):1147-1157. PubMed ID: 31272565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sex difference in heart failure risk associated with febuxostat and allopurinol in gout patients.
    Cheng CL; Yen CT; Su CC; Lee CH; Huang CH; Yang YK
    Front Cardiovasc Med; 2022; 9():891606. PubMed ID: 36035929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular effects of urate-lowering therapies in patients with chronic gout: a systematic review and meta-analysis.
    Zhang T; Pope JE
    Rheumatology (Oxford); 2017 Jul; 56(7):1144-1153. PubMed ID: 28379501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Xanthine oxidase inhibitors for prevention of cardiovascular events: a systematic review and meta-analysis of randomized controlled trials.
    Bredemeier M; Lopes LM; Eisenreich MA; Hickmann S; Bongiorno GK; d'Avila R; Morsch ALB; da Silva Stein F; Campos GGD
    BMC Cardiovasc Disord; 2018 Feb; 18(1):24. PubMed ID: 29415653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol: Population-Based Cohort Study.
    Zhang M; Solomon DH; Desai RJ; Kang EH; Liu J; Neogi T; Kim SC
    Circulation; 2018 Sep; 138(11):1116-1126. PubMed ID: 29899013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Uric Acid Is a Biomarker of Oxidative Stress in the Failing Heart: Lessons Learned from Trials With Allopurinol and SGLT2 Inhibitors.
    Packer M
    J Card Fail; 2020 Nov; 26(11):977-984. PubMed ID: 32890737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of xanthine oxidase inhibitor in patients with chronic heart failure complicated with hyperuricemia: a prospective randomized controlled clinical trial of topiroxostat vs allopurinol-study protocol.
    Sakuma M; Toyoda S; Arikawa T; Koyabu Y; Kato T; Adachi T; Suwa H; Narita JI; Anraku K; Ishimura K; Yamauchi F; Sato Y; Inoue T;
    Clin Exp Nephrol; 2018 Dec; 22(6):1379-1386. PubMed ID: 29916098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role of Xanthine Oxidase Inhibitors in Patients with History of Stroke: A Systematic Review.
    Britnell SR; Chillari KA; Brown JN
    Curr Vasc Pharmacol; 2018; 16(6):583-588. PubMed ID: 28933307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The ongoing search for a stratified medicine approach in heart failure.
    Tang WH
    J Am Coll Cardiol; 2008 Jun; 51(24):2310-2. PubMed ID: 18549914
    [No Abstract]   [Full Text] [Related]  

  • 17. Oxipurinol: alloxanthine, Oxyprim, oxypurinol.
    Drugs R D; 2004; 5(3):171-5. PubMed ID: 15139781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study.
    Hare JM; Mangal B; Brown J; Fisher C; Freudenberger R; Colucci WS; Mann DL; Liu P; Givertz MM; Schwarz RP;
    J Am Coll Cardiol; 2008 Jun; 51(24):2301-9. PubMed ID: 18549913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lesinurad: A Review in Hyperuricaemia of Gout.
    Deeks ED
    Drugs Aging; 2017 May; 34(5):401-410. PubMed ID: 28425024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What is the effect on cardiovascular events of reducing hyperuricemia with allopurinol? An evidence-based review.
    Guedes M; Esperança A; Pereira AC; Rego C
    Rev Port Cardiol; 2014 Nov; 33(11):727-32. PubMed ID: 25444231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.